This is a Multicenter, observational, non-interventional registry designed to collect clinical data in Chinese patients who have received CUBICIN treatment under condition of actual usage in clinical practice.
MC MD
Study Type
OBSERVATIONAL
Enrollment
203
Research Site
Beijing, Beijing Municipality, China
Research Site
Fuzhou, Fujian, China
Research Site
Xiamen, Fujian, China
AEs of CUBICIN therapy
Time frame: 2 weeks
clinical response of CUBICIN therapy at each available time point
Time frame: 2 weeks
CPK level monitoring and results
Time frame: 2 weeks
treatment duration
Time frame: 2 weeks
Time to clinical response
Time frame: 2 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Zhangzhou, Fujian, China
Research Site
Guangzhou, Guangdong, China
Research Site
Xingtai, Hebei, China
Research Site
Haerbing, Heilongjiang, China
Research Site
Zhenzhou, Henan, China
Research Site
Wuhan, Hubei, China
Research Site
Changzhou, Jiangsu, China
...and 8 more locations